Trevena Announces TRV027 Selected for Study in Global REMAP-CAP Trial in COVID-19 PatientsGlobeNewsWire • 04/21/21
Trevena, Inc. Announces Presentations of OLINVYK™ Health Economic Models at AMCP 2021 Annual MeetingGlobeNewsWire • 04/15/21
Trevena, Inc. (TRVN) CEO Carrie Bourdow on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/09/21
Trevena to Release Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021GlobeNewsWire • 03/05/21
Trevena, Inc. Announces Publication Highlighting OLINVYK™ Respiratory Safety Data in High-Risk Patients in Pain & TherapyGlobeNewsWire • 01/28/21
Trevena, Inc. Announces Presentations Highlighting Novel S1P1 Receptor Modulator at the American College of Neuropsychopharmacology 59th Annual MeetingGlobeNewsWire • 12/10/20
Trevena, Inc. Announces Publication Highlighting GI Tolerability Profile of OLINVYK™ (oliceridine) injection in Pain and TherapyGlobeNewsWire • 11/20/20
Trevena, Inc. to Participate in the Following November Virtual Investor ConferencesGlobeNewsWire • 11/09/20
Trevena, Inc. Announces Three OLINVYK™ Presentations at the Virtual American Society of Anesthesiologists 2020 Annual MeetingGlobeNewsWire • 10/05/20
Trevena, Inc. Announces Presentations at the Virtual 2020 American College of Clinical Pharmacology Annual MeetingGlobeNewsWire • 09/21/20
Is the Options Market Predicting a Spike in Trevena (TRVN) Stock?Zacks Investment Research • 09/18/20